Table 2.
Characteristics of studies assessing risk of developing hepatocellular carcinoma
| Author and year | Number of patients | PNPLA3 genotypes | Study location | Patient population | Study design | Liver disease etiology | Number of patients with HCC |
|---|---|---|---|---|---|---|---|
| Corradini (41) | 221 | Not available | Europe | Caucasian | Retrospective cohort | HCV cirrhosis | 141 |
| Falletti (42) | 483 | 35% CC 45% CG 20% GG |
Europe | Caucasian | Retrospective cohort | Mixed cirrhosis cohort | 91 |
| Guyot (43) | 532 | 47% CC 39% CG 14% GG |
Europe | Caucasian | Prospective cohort | Mixed cirrhosis cohort | 159 |
| Hamza (44) | 304 | Not available | Europe | Not reported | Case control | Mixed cirrhosis cohort | 152 |
| Liu (45) | 318 | 42% CC 44% CG 14% GG |
Europe | Caucasian | Retrospective cohort | NAFLD | 33 |
| Nischalke (46) | 322 | 42% CC 44% CG 14% GG |
Europe | Caucasian | Case control | Mixed cirrhosis cohort | 161 |
| Takeuchi (47) | 107 | 7% CC 39% CG 53% GG |
Japan | Japanese | Case control | NAFLD | 50 |
| Trepo (48) | 325 | Not available | Europe | Caucasian | Retrospective cohort | Alcohol-related cirrhosis | 50 |
| Valenti (29) | 325 | 50% CC 39% CG 11% GG |
Europe | Caucasian | Retrospective cohort | HCV | 50 |
HCC, hepatocellular carcinoma; HCV, Hepatitis C virus; NAFLD, nonalcoholic fatty liver disease.